(3.236.86.184)
[ij] [ij] [ij] 
Email id
 

International Journal of Medical Research & Health Sciences
Year : 2016, Volume : 5, Issue : 6
First page : ( 191) Last page : ( 197)
Online ISSN : 2319-5886.

Chromatographic determination of alpha beta momocharin and its effects with the combination of temozolamide and vinblastine in the treatment of glioma cancer In-Vivo

Manoharan Gunasekar*, Bratty Mohammed Al

Pharmaceutical Chemistry Department, College of Pharmacy, Jazan University, Alrawda Dist, Jazan, 82726, Saudi Arabia

*Correspondence E-mail: shekarphd@yahoo.com

Online published on 29 September, 2018.

Abstract

Prior to the availability of chemotherapeutic agents, dietary measures, including traditional medicines derived from plants, were the major forms of cancer treatment. One such plant is M.charantia (Family: Cucurbitaceae), whose fruit is known as Karela or bitter gourd. M.charantia is believed to posse's anti-carcinogenic properties and it can modulate its effect via xenobiotic metabolism and oxidative stress. Different concentration (200μM -800μM)of the alpha and beta momorcharin a protein extracted from bitter gourd fruit, were treated (24 hrs incubation) separately with six different cancer cell lines 1321N1, Gos-3, U87-MG, Sk Mel, Corl -23, Weri Rb-1 and normal L6 muscle cell line. The results also show that combining either temozolomide (240 μM) or vinblastine (40 μg) with (800 μM) alpha and beta momorcharin, result in significant decreases in cell viability for each cell line, these effects were additive compared to the individual effect of temozolomide or vinblastine.

Top

Keywords

Cancer cell lines, Momordicacharantia (MC)alpha, beta momorcharin (α, β), temozolomide (TMZ) andvinblastine (VIB).

Top

 
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
813,241,011 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.